CN Patent

CN104203953B — (s)‑4‑氨基‑n‑(1‑(4‑氯苯基)‑3‑羟丙基)‑1‑(7h‑吡咯并[2,3‑d]嘧啶‑4‑基)哌啶‑4‑甲酰胺的晶型

Assigned to AstraZeneca AB · Expires 2016-11-16 · 9y expired

What this patent protects

本发明公开了( S )‑4‑氨基‑ N ‑(1‑(4‑氯苯基)‑3‑羟丙基)‑1‑(7H‑吡咯并[2,3‑ d ]嘧啶‑4‑基)哌啶‑4‑甲酰胺的某些新固态形式、用于制备这种固态形式的方法、包含这种固体形式的药物组合物、和这种形式在治疗中的用途。

USPTO Abstract

本发明公开了( S )‑4‑氨基‑ N ‑(1‑(4‑氯苯基)‑3‑羟丙基)‑1‑(7H‑吡咯并[2,3‑ d ]嘧啶‑4‑基)哌啶‑4‑甲酰胺的某些新固态形式、用于制备这种固态形式的方法、包含这种固体形式的药物组合物、和这种形式在治疗中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN104203953B
Jurisdiction: CN
Classification: —
Expires: 2016-11-16
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.